Immunotherapy Strategies for Gastrointestinal Stromal Tumor
Open Access
- 14 July 2021
- Vol. 13 (14), 3525
- https://doi.org/10.3390/cancers13143525
Abstract
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal soft tissue sarcoma of the gastrointestinal tract. The management of locally advanced or metastatic unresectable GIST involves detecting KIT, PDGFR, or other molecular alterations targeted by imatinib and other tyrosine kinase inhibitors. The role of immunotherapy in soft tissue sarcomas is growing fast due to multiple clinical and pre-clinical studies with no current standard of care. The potential therapies include cytokine-based therapy, immune checkpoint inhibitors, anti-KIT monoclonal antibodies, bi-specific monoclonal antibodies, and cell-based therapies. Here we provide a comprehensive review of the immunotherapeutic strategies for GIST.Keywords
This publication has 36 references indexed in Scilit:
- Gastrointestinal Stromal TumorsHematology/Oncology Clinics of North America, 2013
- An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST)Journal of Medical Genetics, 2013
- Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumorJournal of Translational Medicine, 2013
- Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growthProceedings of the National Academy of Sciences of the United States of America, 2013
- Exploiting antitumor immunity to overcome relapse and improve remission durationCancer Immunology, Immunotherapy, 2011
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature Medicine, 2011
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumorsNature Medicine, 2011
- Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumorsInternational Journal of Cancer, 2009
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJournal of Clinical Oncology, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002